
‘China’s Ozempic’ may vie with Eli Lilly, Novo Nordisk for global weight-loss drug market
The global market for diabetes drugs used for treating obesity is expected to expand in Asia, as new players jostle with giants Eli Lilly and Novo Nordisk for a share of the multibillion-dollar industry, with China providing a big opportunity for growth, …